MIVT Licenses New Technologies for Next-Generation Device Coatings

MIV Therapeutics (MIVT), a developer of next-generation biocompatible stent coatings and drug-delivery technologies, has exercised an option in the collaborative research agreement with The University of British Columbia (UBC) to license two new technologies for advanced biocompatible coatings for cardiovascular stents and other medical devices.

The technologies licensed from UBC involve enhanced applications of MIVT's Hydroxyapatite (HAp) coating. HAp is a ceramic material that has demonstrated excellent biocompatibility when used to coat medical devices, such as stents, that are implanted in the human body.

The new license will grant MIVT exclusive rights to advanced methods developed under the agreement for processing and applying HAp to implantable medical devices. One patent, "Calcium Phosphate Coatings for Coronary Stents by Electrochemical Deposition," discloses a new process for electrochemical deposition of HAp coatings on medical devices, including special preparation of metallic surfaces to ensure a high level of adhesion to the substrate. Another patent, "Calcium Phosphate Coatings for Coronary Stents by Electrophoretic Deposition," describes an alternative method of establishing uniform microporous HAp coatings on cardiovascular stents, through an electrophoretic deposition.